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DNA vaccination elicits humoral and cellular immune responses and has been shown to confer protection
against several viral, bacterial, and parasitic pathogens. Here we report that optimized codon usage of an
injected DNA sequence considerably increases both humoral and cellular immune responses. We recently
generated a synthetic human immunodeficiency virus type 1 gp120 sequence in which most wild-type codons
were replaced with codons from highly expressed human genes (syngp120). In vitro expression of syngp120 is
considerably increased in comparison to that of the respective wild-type sequence. In BALB/c mice, DNA
immunization with syngp120 resulted in significantly increased antibody titers and cytotoxic T-lymphocyte
reactivity, suggesting a direct correlation between expression levels and the immune response. Moreover,
syngp120 is characterized by rev-independent expression and a low risk of recombination with viral sequences.
Thus, synthetic genes with optimized codon usage represent a novel strategy to increase the efficacy and safety
of DNA vaccination.
It has been shown that “naked” DNA administered to ani-
mals is taken up by cells and expressed (21, 30, 66). Inoculated
plasmid DNAs expressing foreign genes induce humoral and
cellular immune responses and thus can be used for vaccina-
tion (46, 58, 67). In animal models, DNA vaccination has been
shown to induce protective immunity against a variety of viral,
bacterial, and parasitic pathogens. Inoculation of plasmid
DNAs conferred protection against challenges with influenza
virus (46, 61), rabies virus (68), herpes simplex virus (37),
papillomavirus (16), lymphocytic choriomeningitis virus (72),
and flavivirus (44) but also against tuberculosis (28, 59), leish-
maniasis (69), and malaria (17, 54). Plasmid DNAs expressing
genes derived from simian immunodeficiency virus or human
immunodeficiency virus (HIV) were recently shown to induce
humoral and cellular immune responses in rodents (64, 65), in
nonhuman primates (6, 12, 34, 42, 71), and in phase I and II
studies with humans (unpublished data). Although these con-
structs were able to induce an immune response, both circu-
lating antibody titers and HIV type 1 (HIV-1)-specific cyto-
toxic T-lymphocyte (CTL) levels were transient and low. As
there are several lines of evidence for a correlation among
protection, clinical course, and immune responses from previ-
ous studies on mother-to-infant transmission of HIV (24, 48,
49), repeatedly HIV-exposed but uninfected individuals from
high-risk groups (50), human long-term survivors (8, 43), and
vaccination trials with nonhuman primates (7, 26), we sought
to increase the efficacy of DNA vaccines expressing HIV genes.
We generated a synthetic gp120 sequence in which codon
usage was optimized for expression in human cells (syngp120)
(25). In this study, the syngp120 sequence induced a consider-
ably higher immune response than did the respective wild-type
sequence, suggesting that the efficacy of DNA vaccines can be
significantly improved by optimization of translational signals.
MATERIALS AND METHODS
Plasmid constructs. The syngp120 sequence was previously generated by use
of eight long synthetic oligonucleotides, which were amplified by a PCR with
overlapping primers with unique restriction sites; the oligonucleotides were sub-
sequently subcloned into a pCdm7-derived plasmid with a suitable polylinker 39
to the CD5 signal peptide sequence (25). A wild-type gp120 sequence from either
HIV-1 LAI (gp120LAI) or HIV-1 MN (gp120MN) were similarly expressed in
pCdm7 under control of the human cytomegalovirus immediate-early promoter
(55). In some experiments, wild-type gp120 sequences in which the endogenous
signal sequence was replaced with the CD5 signal sequence were used (see Fig.
4 and 5) (25). There was no difference in antibody induction between constructs with
the endogenous signal sequence and the CD5 signal sequence. syngp120v3LAI, used
for immunization of mice tested in CTL assays, was generated by subcloning of a
111-mer oligonucleotide adapter into the MluI and XbaI restriction sites of
syngp120. gp120MNrre, gp120LAIrre, syngp120rre, and syngp120v3LAIrre were
generated by inserting a 0.24-kb fragment containing the HIV-1 rev-responsive
element (RRE) into the NotI restriction site of the respective plasmids. pCMV-rev
was kindly provided by the National Institutes of Health AIDS repository.
Cell lines. 293T (adenovirus-transformed human kidney cells), HeLa (human
cervical carcinoma cells), NIH 3T3 (murine fibroblasts), and COS-7 (African
green monkey kidney cells) were maintained in Dulbecco’s modified Eagle me-
dium (Life Technologies, Paisley, Scotland) supplemented with 10% heat-inac-
tivated fetal calf serum (FCS), 100 IU of penicillin per ml, 100 mg of streptomycin
per ml, and 2 mM L-glutamine. P815 (murine mastocytoma cells) and B7, a
P815-derived cell line expressing the costimulatory molecule B7, were main-
tained in RPMI medium supplemented with 5% FCS, 100 IU of penicillin per ml,
100 mg of streptomycin per ml, and 0.05 mM 2-mercaptoethanol.
Immunoprecipitation. Cells were transfected by calcium phosphate coprecipi-
tation with 10 mg of plasmid DNA per 6-cm tissue culture dish according to
standard protocols (51). In brief, precipitated DNA was incubated with cells at
approximately 70% confluence for 8 to 12 h. After 100 mM chloroquine was
added for an additional 4 h, the culture medium was exchanged. At 3 days
posttransfection, cells were metabolically labelled with 200 mCi of [35S]Cys/Met
per dish. Supernatants were immunoprecipitated with human antiserum 95-1
from an HIV-infected patient and analyzed by reducing sodium dodecyl sulfate
(SDS)–7% polyacrylamide gel electrophoresis (PAGE).
Nucleic acid immunization. BALB/c mice (Jackson Laboratories) were immu-
nized with 50 mg of plasmid DNA (in 50 ml of phosphate-buffered saline [PBS])
in both anterior tibial muscles that had been pretreated with cardiotoxin (50 ml
of a 10 mM cardiotoxin solution) from Naja nigricollis (Latoxan, Rosans, France)
as reported previously (52). Sera were drawn from the tail vein after various
intervals.
Cytotoxicity assay. CTLs were prepared from spleen cells of sacrified mice by
culturing in alpha minimal essential medium (Life Technologies) supplemented
with 10 mM HEPES buffer, 0.05 mM 2-mercaptoethanol, 100 IU of penicillin per
ml, 100 mg of streptomycin per ml, and 10% heat-inactivated FCS. After 5 days,
interleukin 2 was added at a concentration of 100 U/ml; after an additional 2
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days, peptide-loaded B7 cells irradiated with 80,000 rads were added at a ratio of
1:2. Cytotoxic effector cells were restimulated every 2 weeks and harvested after
various intervals. Cytolytic activity was measured with a standard 51Cr release
assay. In brief, 103 51Cr-labelled P815 target cells per well were incubated for 1 h
at 37°C with titrated amounts (1027 to 10213 M) of the nonamer peptide
GPGRAFVTI, constituting the crown of the HIV-1 LAI v3 loop. Subsequently,
104 effector cells were added to each well and incubated for 4 h at 37°C. Finally,
100 ml of supernatant was harvested from each well and analyzed in a Canberra
Packard microplate scintillation counter. Specific release was calculated with the
formula [(experimental release 2 spontaneous release)/(total release 2 sponta-
neous release)] 3 100. All data are means of results for triplicate cultures.
ELISA. Sera from immunized mice were tested for antibodies directed against
HIV-1 gp120 by either an enzyme-linked immunosorbent assay (ELISA) or
Western blotting. ELISA microtiter plates were coated with 1 mg of a CD4-
immunoglobulin G (IgG) fusion protein (kindly provided by Behring, Marburg,
Germany) per well overnight and washed four times; subsequently, blocking was
done with PBS–0.2% Tween for 2 h. After removal of the blocking solution, 100
ml of supernatant from 293T cells transfected with syngp120 was added and
incubated for 90 min. The supernatant was discarded, and 100 ml of prediluted
mouse serum was added and incubated for 1 h. Microtiter plates were washed
four times and incubated with a secondary, peroxidase-coupled anti-mouse IgG
antibody (Jackson Laboratories). Finally, ELISA plates were washed, 200 ml of
2,29-azinobis(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS) substrate (Boehr-
inger GmbH, Mannheim, Germany) was added per well, and the optical density
at 405 nm was measured after 15 min. The optical density of control wells without
mouse serum was between 0 and 0.2 (in most cases, below 0.1).
Western blotting. Virus stocks were isolated from supernatants of H9 cells
infected with HIV-1 MvP899, purified by sucrose density gradient centrifugation,
and subjected to denaturing SDS–12% PAGE. The gel was blotted onto a
polyvinylidene difluoride membrane (Millipore, Bedford, Mass.), blocking was
done with 1% nonfat dry milk powder, and the gel was cut into strips. Mouse sera
were diluted 1:100 in PBS and reacted with individual strips for 1 h. Subse-
quently, strips were washed four times with Tris-buffered saline–0.2% Tween,
reacted with a peroxidase-coupled antiserum against mouse IgG (Jackson Lab-
oratories), and incubated with diaminobenzidine substrate (Sigma, St. Louis,
Mo.).
Statistical analysis. Statistical analysis was done with the Kruskal-Wallis test
and SAS release 6.08 TS407 software (SAS Inc., Cary, N.C.).
RESULTS
The expression of cloned HIV-1 env sequences in eukaryotic
expression plasmids is inefficient due to poorly characterized
negative sequence elements, which can be found throughout
the HIV-1 genome (11, 18, 40, 47, 53). Inhibition appears to be
partly caused by elements mediating nuclear mRNA retention,
which can be reversed by Rev, a regulatory HIV-1 protein
promoting the export of unspliced viral RNA into the cyto-
plasm (18–20, 36). However, even HIV-1 transcripts located in
the cytoplasm are insufficiently expressed due to low transla-
tional efficiency caused by a highly distinct codon bias for
adenine and thymine at the third codon position. Codon usage
in env is very similar in all primary and laboratory HIV-1
isolates, is independent of subtype and phenotype, and is strik-
ingly divergent from that of highly expressed human genes, in
which predominantly codons with cytosine and guanine at the
FIG. 1. Codon bias in the HIV-1 envelope gene. Codon frequencies in the HIV-1 envelope gene (black boxes) and in highly expressed human genes (shaded boxes)
were calculated by use of standard software from the University of Wisconsin Genetics Computer Group and sequences derived from the Los Alamos National Library
database. Codon frequencies were tabulated with 24 different HIV-1 envelope sequences from the following isolates: Ada, Ant70, Br0141, Br0259, JFL, JRCSF, JY1,
LAI, M12199, MaI, MN, MVP5180, RF, Rw0914, SF2, SF162, SF33, T8659, Th1412, Ug0205, Ug0317, Ug0378, ZAM20, and Z6649. Codon frequencies from highly
expressed cellular genes are listed according to the work of Cherry (10). The most frequently used codon for every amino acid is underlined.
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third codon position are found (Fig. 1). To test the effect of
codon preference in env, we generated syngp120, which has an
amino acid sequence 100% identical to that of the HIV-1 MN
isolate (subtype B) and in which all wild-type codons are re-
placed by codons used in highly expressed human genes (25).
Levels of expression of the syngp120 sequence are considerably
increased in comparison to that of the wild-type gp120 se-
quence and, moreover, are independent of the Rev regulatory
protein. In various mammalian cell lines, significantly more
glycoprotein could be immunoprecipitated from supernatants
of cells transiently transfected with the syngp120 sequence
than with the wild-type gp120 sequence (Fig. 2). The difference
in expression levels between the synthetic and the wild-type
constructs depends on the expression system and the tissue
transfected. In 293T cells transiently transfected with the eu-
karyotic expression vector pCdm7, there is usually a 10- to
50-fold increase in expression levels with the synthetic gene.
In DNA inoculation, the expression of injected genes is
influenced by the promoter used (9, 38). The immune response
was shown to be modulated in some but not in all cases by the
promoter (4, 62, 73). We thus speculated that codon usage
modulates the immune response and compared results with
plasmids carrying genes expressing the syngp120 sequence and
the respective wild-type gp120 sequence. Plasmid DNA encod-
ing either gene subcloned in an identical vector backbone was
inoculated into the anterior tibial muscles of BALB/c mice and
tested for antibody and CTL induction. A total of 75 BALB/c
mice (17 controls, 29 receiving wild-type gp120, and 29 receiv-
ing syngp120) were immunized in six separate experiments.
Mice immunized with the syngp120 gene developed consider-
ably higher antibody titers than mice injected with the wild-
type gp120 gene (Kruskal-Wallis test, P , 0.00479). One pro-
totypic experiment is shown in Fig. 3. In this experiment,
injection of plasmid DNA containing syngp120 resulted in high
concentrations of anti-gp120 antibodies in three of four mice,
whereas one mouse developed no measurable antibody re-
sponse. In contrast, all mice inoculated with a plasmid contain-
ing wild-type gp120 developed no or only barely detectable
antibodies with this immunization schedule. Similar results
were achieved with gp120LAI, indicating that the low produc-
tion of antibodies was due to neither the particular virus strain
nor the plasmid construct used (data not shown). Since in vitro
in transiently transfected cells the expression of wild-type
gp120 but not of syngp120 can be increased when the post-
translational transactivator Rev is supplied in trans and the
RRE is supplied in cis, we coinjected plasmid pCMV-rev ex-
pressing HIV-1 Rev with plasmids containing an RRE 39 to the
gp120 coding region and tested for antibody induction (Fig. 4).
FIG. 2. Increased expression of syngp120 in various mammalian cell lines in
vitro. 293T (adenovirus-transformed human kidney cells), HeLa (human cervix
carcinoma cells), NIH 3T3 (mouse fibroblasts), and COS-7 (African green mon-
key kidney cells) were transiently transfected by calcium phosphate coprecipita-
tion with plasmids carrying genes coding for either wild-type gp120MN (wt) or
syngp120 (syn). Culture supernatants of radioactively labelled cells were immu-
noprecipitated with a human antiserum derived from an HIV-1-infected individ-
ual and analyzed on a reducing SDS–7% PAGE.
FIG. 3. Increased humoral immune responses of BALB/c mice immunized
with syngp120. ELISA analysis of sera from mice immunized with plasmid DNA
encoding either syngp120 (filled symbols) or wild-type gp120 MN (open sym-
bols). IgG antibody reactivity against gp120 in sera from DNA-inoculated mice
was measured by an ELISA. Mice were either immunized once (wt 1, wt 2, syn
1, and syn 2) or immunized and boosted three times after 2, 4, and 6 weeks (wt
3, wt 4, syn 3, and syn 4). Sera were drawn from the tail vein 3 (wt 1, wt 2, syn
1, and syn 2) or 10 (wt 3, wt 4, syn 3, and syn 4) weeks after the initial
immunization. OD405, optical density at 405 nm; wt, wild type; syn, syngp120.
FIG. 4. Increased humoral immune responses of BALB/c mice immunized
with syngp120 independently of the regulatory protein Rev. Western blot analysis
of sera from mice immunized with pCdm7 (lanes 1 to 3), gp120MNrre and
pCMV-rev (lanes 4 to 9), or syngp120v3LAIrre and pCMV-rev (lanes 10 to 15)
is shown. Western blot strips prepared with the HIV-1 MvP899 isolate were
reacted with sera derived from either DNA-injected mice (lanes 1 to 15) or an
HIV-1-infected individual (lane 16). Mice were immunized twice, and serum was
collected 12 weeks after the initial immunization. wt, wild type.
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We were able to detect antibodies directed against gp120/
gp160 in four of six mice immunized with the syngp120 se-
quence but in none injected with the wild-type gp120 sequence,
indicating that even in the presence of Rev and the RRE the
induction of antibodies was increased with the synthetic se-
quence.
The induction of CTLs was tested with spleen cells isolated
from DNA-immunized mice as effector cells and peptide-
loaded P815 mouse mastocytoma cells as target cells. The
GPGRAFVTI nonamer peptide used in this assay is known to
constitute a Dd-restricted CTL epitope in mice. For evaluation
of the cellular immune response, a total of 16 mice (four
controls, 6 receiving wild-type gp120, and 6 receiving
syngp120) were tested in two experiments. Like antibody pro-
duction, CTL responses in mice immunized with syngp120
were significantly higher than those in mice injected with wild-
type gp120 (Kruskal-Wallis test with 1027 M peptide concen-
tration, P , 0.01; with 1027 to 1029 M peptide concentration,
P , 0.001). In the experiment shown in Fig. 5, the cellular
immune response was increased in mice immunized with the
syngp120 sequence and again was barely detectable in mice
immunized with the wild-type gp120 sequence. Differences in
the immune responses of mice treated with wild-type gp120
and syngp120 constructs were not caused by a delayed time
course in mice inoculated with the wild-type sequence (Fig. 6).
Even multiple boosts with the wild-type sequence over a period
of 5 months did not significantly increase antibody production.
DISCUSSION
In this study, we showed that DNA immunization with a
synthetic sequence with optimized codon usage resulted in
considerably increased humoral and cellular immune re-
sponses. Protection against HIV or simian immunodeficiency
virus has been achieved in some animal models, with different
vaccines. In primate models in which a rather avirulent virus
challenge was used, vaccines inducing a limited immune re-
sponse (like that induced by subunit vaccines, recombinant
vectors, and peptides) were protective (3, 5, 56); however, in
more pathogenic animal models, only live attenuated virus was
successful (1, 13). These results suggest that a potential vaccine
meeting safety requirements for humans can only be successful
if strategies to increase immunogenicity are developed.
Our in vitro data with transfected cells lines suggest that the
difference between the syngp120 and wild-type gp120 se-
quences is caused by different expression levels in muscle cells.
In a previous study, we showed that there is no difference in
cytoplasmic RNA levels in cells transfected with either wild-
type gp120 or syngp120, indicating that the difference in pro-
tein levels is most likely a purely translational effect (25).
However, an alternative explanation for the enhanced immune
response might be the increase in CpG motifs in the synthetic
gene administered. Recently, several groups were able to show
that DNA containing unmethylated CpG motifs, such as bac-
terial DNA, is able to trigger B-cell activation (33, 45, 70).
Moreover, Klinman and colleagues suggested that unmethyl-
ated CpG motifs might also contribute to the immunogenicity
of gene vaccines (32). As a considerable number of CpG mo-
tifs, 92, have been introduced into the gp120 sequence by
codon exchange, it is possible that they contribute to the in-
creased immunogenicity of the syngp120 sequence.
With the wild-type gp120 sequence, we obtained low or
undetectable antibody and CTL activities, in contrast to results
in some of the earlier reports on DNA immunization with
HIV-1-derived genes (12, 22, 35, 64, 65, 71). In in vitro trans-
fection experiments, we are able to detect gp120 expressed
from wild-type sequences when gels were exposed longer (25).
However, in Fig. 2, a rather short exposure is shown because
otherwise the autoradiography would have been overexposed
due to the strong signal of syngp120. Moreover, as can be seen
in Fig. 3 and 5, at least in some animals there was low but
specific antibody (wt 3; Fig. 3) and CTL (wt2; Fig. 5) induction
by the wild-type constructs that we used, indicating that gp120
is expressed from these constructs. Thus, low or undetectable
immune responses with wild-type gp120 sequences can be ex-
plained not by cloning artifacts (e.g., by PCR cloning) but
rather by the fact that we tried to improve neither our inocu-
lation protocols nor the assays measuring antibody and CTL
responses and consequently used both inefficient delivery con-
ditions and detection assays. For example, the number of non-
responders, which might be reflective of the vector or the
immunization technique used, could probably be decreased
with gene-gun DNA delivery (23). Further improvement might
be achieved with cytokine or cytokine-plasmid adjuvants, as
has been shown previously (27, 29, 31, 73). The use of vectors
coexpressing both gp120/gp160 and Rev or vectors with rev-
independent gp120 expression might be helpful as well, al-
though there are no hints in the literature suggesting that they
induce a higher immune response than do coinjected env- and
rev-expressing plasmids (6, 22, 34, 42, 64, 65). Moreover, in
view of the potential interference with other cellular genes and
potential use in humans, the introduction of genes coding for
regulatory proteins is disadvantageous, and expression systems
which are rev independent are preferable. Another major ad-
FIG. 5. Increased cellular immune responses of BALB/c mice immunized
with syngp120. CTL assay of spleen cells from DNA-injected mice against target
cells loaded with titrated amounts of the nonamer peptide GPGRAFVTI.
BALB/c mice were immunized with 40 mg of either pCDM7 (CDM71 to CDM73;
negative control), syngp120v3LAIrre (syn1 to syn4), or gp120LAIrre (wt1 to wt4)
and 10 mg of pCMV-rev, boosted twice after 6 and 30 weeks, and sacrified after
an additional 3 weeks. Spleen cells were restimulated with interleukin 2 and
peptide-loaded B7 cells in vitro. Data are mean percentages of three replicate
cultures. Killing was antigen specific and not caused by NK cells, as wells without
peptide did not show any chromium release (,5% specific release in all mice).
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vantage of syngp120 is the low homology to viral sequences on
the nucleic acid level, which considerably reduces the risk of
homologous recombination with latent or defective viral ge-
nomes. Although relatively little is known about sequence re-
quirements for homologous recombination in mammalian
cells, it appears that DNA sequence mismatching presents a
considerable barrier to homologous recombination in a wide
variety of systems (14, 41, 57, 60, 63). As almost every third
nucleotide has been exchanged in the syngp120 sequence and
the longest stretch of identical nucleotides has a length of only
14 bp, it is conceivable that the risk of recombination is con-
siderably decreased. Thus, in terms of safety issues, there are at
least two aspects which argue in favor of the approach pre-
sented here.
The antibody response was tested by means of either an
ELISA or Western blotting. The Western blot strips were
prepared with HIV-1 isolates MvP899 (Fig. 4) and LAI (data
not shown). Interestingly, sera from mice immunized with the
syngp120 gene with the HIV-1 isolate MN amino acid se-
quence cross-reacted with both MvP899 and LAI strips. In the
influenza virus system, there is evidence that DNA vaccines
induce a broader immunity than subunit or inactivated-virus
vaccines (15, 39). The induction of cross-reactive immunity
might be further increased with a multigene DNA immuniza-
tion strategy, as has been shown previously with malaria (17)
and mycoplasma (2). The synthetic sequence presented here
appears to be suitable for a similar multigene approach, since
unique restriction sites have been introduced into the synthetic
env sequence over an approximately 100-bp distance, allowing
the generation of chimeric molecules with exchanged domains
from other virus isolates. Alternatively, it might be useful to
increase the number of potential epitopes by coinjection of
DNA plasmids carrying other HIV genes, as was shown in a
previous report, in which two vectors expressing env and gag/
pol conferred protection against a heterologous HIV-1 chal-
lenge in chimpanzees (5).
In summary, codon optimization of the HIV-1 env gene
appears to be advantageous because of (i) increased humoral
and cellular immune responses, (ii) rev-independent expres-
sion, (iii) a low risk of recombination due to little homology to
viral sequences, and (iv) potential use in a multigene approach.
The putative superiority of this method needs to be addressed
in future protection studies with macaques and humans by use
of a single-gene or multigene approach. In more general terms,
the data presented here suggest a similar strategy for genes
from other pathogens used in DNA vaccination and for cellu-
lar genes used in gene therapy.
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